Just days after officials in India stripped Bayer ($BAY) of its exclusive rights to Nexavar, giving a local company the right to produce it at a deep discount, Roche ($RHHBY) has stepped up with plans to slash the cost of two of its blockbuster cancer drugs. Herceptin and MabThera will be offered in cheaper new versions from an Indian partner. "The scope is to enable access for a large majority of patients who currently pay out of pocket as well as to partner with the government to enable increased access to our products for people in need," a Roche spokesperson told Reuters. Report